Published in Bone Marrow Transplant on August 17, 2015
Pembrolizumab After ASCT for Hodgkin Lymphoma and DLBCL | NCT02362997
Lenalidomide Maintenance Therapy Post Autologous Transplant for Hodgkins Lymphoma | NCT01207921
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia | NCT01403636
Lenalidomide and GA101 in Relapsed Indolent Non-Hodgkin's Lymphoma | NCT01995669
Carfilzomib Plus Belinostat in Relapsed/Refractory NHL | NCT02142530
Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma | NCT00838955
Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma | NCT01849263
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature (2000) 64.32
Selective inhibition of BET bromodomains. Nature (2010) 18.79
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med (2014) 10.10
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature (2010) 8.78
Oncogenically active MYD88 mutations in human lymphoma. Nature (2010) 7.34
Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood (2005) 7.28
Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene (2007) 7.13
Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther (2009) 6.91
Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med (2003) 6.81
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol (2012) 6.78
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med (2013) 6.70
Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science (2008) 6.52
CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest (2011) 6.38
Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med (2003) 6.06
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol (2012) 5.86
Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A (1993) 5.23
CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood (2010) 4.69
Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol (2012) 4.41
Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol (2014) 3.94
Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A (2005) 3.86
PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med (2014) 3.86
Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol (2013) 3.77
T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood (2002) 3.57
Treatment of older patients with mantle-cell lymphoma. N Engl J Med (2012) 3.46
Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol (2004) 3.42
The basic principles of chimeric antigen receptor design. Cancer Discov (2013) 3.28
Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med (2015) 3.18
Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood (2009) 3.17
Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell (2013) 3.13
Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol (2012) 2.94
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol (2004) 2.81
Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol (2003) 2.75
High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol (2003) 2.65
Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol (2012) 2.65
Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol (2015) 2.64
Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood (2010) 2.52
Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402. J Clin Oncol (2014) 2.39
Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J Immunother (2009) 2.35
Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood (2003) 2.31
Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol (2008) 2.23
Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res (2004) 2.23
An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol (2011) 2.12
Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol (2010) 2.08
Gene-engineered T cells for cancer therapy. Nat Rev Cancer (2013) 2.07
Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol (2013) 2.07
Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin Cancer Res (2011) 2.05
Cd4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome. J Clin Oncol (2001) 2.00
Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin Cancer Res (2009) 1.92
Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer (2011) 1.92
Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol (2013) 1.91
Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol (2005) 1.88
Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. Lancet Oncol (2011) 1.81
Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev (2014) 1.81
Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma. Clin Cancer Res (2014) 1.75
BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab. Clin Cancer Res (2011) 1.67
Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. J Clin Oncol (2012) 1.66
Tandem autologous-allogeneic nonmyeloablative sibling transplantation in relapsed follicular lymphoma leads to impressive progression-free survival with minimal toxicity. Biol Blood Marrow Transplant (2011) 1.55
Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation. Blood (1998) 1.55
Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet (1993) 1.53
Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood (2014) 1.53
Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale. J Immunother (2012) 1.47
Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. Future Oncol (2009) 1.47
Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol (2006) 1.45
PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A (2013) 1.44
A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood (2011) 1.44
Allogeneic natural killer cells for refractory lymphoma. Cancer Immunol Immunother (2010) 1.42
Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma. Br J Haematol (2009) 1.28
Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect. Invest New Drugs (2010) 1.27
Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma. Blood (2009) 1.26
Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion. Biol Blood Marrow Transplant (2002) 1.23
Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. Leukemia (2007) 1.22
Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood (1999) 1.21
Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomas. Biol Blood Marrow Transplant (2010) 1.21
Patterns and outcome of relapse after autologous stem cell transplantation for mantle cell lymphoma. Cancer (2010) 1.14
Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. J Clin Oncol (2009) 1.12
Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey. J Clin Oncol (2008) 1.10
Beyond chemotherapy: new agents for targeted treatment of lymphoma. Nat Rev Clin Oncol (2010) 1.10
The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines. Blood (2012) 1.09
Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation. J Immunol (2009) 1.09
Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma. Ann Oncol (2009) 1.07
Histone deacetylase inhibitors: a new class of immunosuppressors targeting a novel signal pathway essential for CD154 expression. Blood (2002) 1.05
Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group. J Clin Oncol (2014) 1.05
Immune reconstitution after autologous hematopoietic stem cell transplantation. Mayo Clin Proc (2001) 1.04
The aggresome pathway as a target for therapy in hematologic malignancies. Mol Genet Metab (2008) 0.99
Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial. Clin Cancer Res (2014) 0.96
Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy. Leuk Lymphoma (2012) 0.96
Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant (2014) 0.95
The unique profile of cord blood natural killer cells balances incomplete maturation and effective killing function upon activation. Hum Immunol (2011) 0.93
Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma. Ann Oncol (2008) 0.93
B-cell depletion for 2 years after autologous stem cell transplant for NHL induces prolonged hypogammaglobulinemia beyond the rituximab maintenance period. Leuk Lymphoma (2008) 0.90
Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: who, when and how? Bone Marrow Transplant (2013) 0.83
Chronic GVHD and concurrent new-onset nephrotic syndrome in allogeneic transplant recipients. Incidence, pattern and therapeutic outcomes. Bone Marrow Transplant (2014) 0.80